The objective of this project was to validate a new high-throughput homogeneous enzyme immunoassay (HEIA) for the rapid detection of carisoprodol in human urine. Carisoprodol (Soma ® ) and meprobamate are widely prescribed as musculoskeletal pain relief drugs and are listed as one of the 10 most frequently identified drugs associated with DUI cases. Carisoprodol has a short elimination half-life of 1-3 h; however, its major active metabolite, meprobamate, has a longer elimination half-life of 6-17 h. As a result, it is important for an immunoassay to cross-react with both compounds. The advantage of this new assay is that cutoff concentrations can be adjusted between 100 and 500 ng/mL. The reportable range was 25 to 1000 ng/mL for carisoprodol and 50 to 10,000 ng/mL for meprobamate. The intraday coefficient of variation (% CV) for the semi-quantitative assay was less than 1%. The homogeneous assay was validated with a total of 86 urine samples previously analyzed by liquid chromatography-tandem mass spectrometry with carisoprodol concentrations ranging from 50 to 10,000 ng/mL. The accuracy was found to be 100% when immunoassay cutoff concentrations of carisoprodol and meprobamate were set at 100 and 1000 ng/mL, respectively.
Introduction
Carisoprodol and meprobamate have been commercially available for over 50 years for the treatment of musculoskeletal pain. Carisoprodol can be metabolized through n-dealkylation reaction to its major active metabolite, meprobamate, and to a lesser extent, by hydroxylation reaction to a hydroxycarisoprodol and hydoxymeprobamate in the liver (Figure 1 ). Carisoprodol has a short elimination half-life of 1-3 h; however, its major active metabolite, meprobamate, is also a prescribed drug and has a longer elimination half-life of 6-17 h and thus a longer detection time than carisoprodol in urine (1, 2) .
The popularity of the drug is due to its pain relief and euphoric effect during treatment, increasing the potential for abuse (3, 4) . The effects of both carisoprodol and meprobamate are similar to those of alcohol, with loss of balance, sedation, and confusion, which is why both of these drugs are on the list of the 10 most identified drugs in DUI cases (5) . In addition, these drugs are frequently present in urine specimens collected from chronic pain patients (6) . Currently, enzyme-linked immunosorbant assay (ELISA) is the only commercially available screening method for the detection of carisoprodol and meprobamate in urine and blood (7) followed by confirmation methods such as liquid chromatography with mass spectral detection (LC-MS-MS) (8-10) or gas chromatography-mass spectrometry (GC-MS) (11, 12) . For this reason, it is highly desirable to develop a novel high-throughput and sensitive homogeneous enzyme immunoassay screening method to detect both carisoprodol and meprobamate in urine. The ratio between parent drug and metabolite could vary dramatically depending on the matrix employed. The "in house" antibody was designed for different matrices such as oral fluid, hair, and the like because they require the detection of the parental drug. This assay also can be used to detect a patient taking meprobamate. As the detection time of meprobamate in urine is 2-10 times longer than carisoprodol because of its higher dosage and slower elimination, the new assay has a lower cross-reactivity for meprobamate.
In this paper, we report the first homogeneous immunoassay that can simultaneously and rapidly detect both carisoprodol and meprobamate in urine specimens. The detection ranges were determined to be 25 to 1000 ng/mL for carisoprodol and 50 to 10,000 ng/mL for meprobamate. Matrix effects and nonrelated drug interferences were not observed.
Experimental

Urine specimens
Eighty-six clinical urine specimens were collected from outside laboratories that also provided confirmation results. The urine specimens were a combination of negative and positive specimens at an LC-MS-MS confirmation cutoff of 50 ng/mL for carisoprodol and 500 ng/mL for meprobamate.
Apparatus and reagents
An Olympus AU400e automatic chemical analyzer was used and was provided by Immunalysis (Pomona, CA). The carisoprodol and meprobamate (1 mg/mL in methanol) drug standards were purchased from Cerilliant (Round Rock, TX). Enzyme reagents and antibody/substrate reagents were provided by Immunalysis; carisoprodol polyclonal antibody and hapten were also provided by Immunalysis. Glucose-6-phosphate dehydrogenase (G6PDH) was purchased from Oriental Yeast (Japan). Drug mixes for cross-reactivity with unrelated drug were all purchased from Discovery Sciences (State College, PA).
Preparation of reagent antibody (RA) and reagent enzyme (RE)
RA was prepared from in-house-raised polyclonal antibody diluted with 20 mM Tris-hydrochloric acid (Tris-HCl) buffer (pH 6.0) containing 0.05 M nicotinamide adenine dinucleotide (NAD) and 0.5% sodium chloride (NaCl). RE was prepared from in-house carisoprodol-G6PDH conjugate diluted with 0.1 M Tris-HCl buffer (pH 7.8) containing 0.2% bovine serum albumin (BSA) and 0.5 M glucose-6-phosphate (G6P).
Principles of homogeneous enzyme immunoassay (HEIA)
The HEIA technique is based on an immunoassay format in which both the antibody (RA) and enzyme-drug conjugate (RE) are in ready-to-use solution. The assay is performed by mixing the sample with reagents RA and RE and requires no separation step. In the absence of the target analyte in the specimen, enzyme-labeled drug conjugate binds to the antibody and results in decrease of the enzyme (G6PDH) activity; hence, there is lower absorbance at 340 nm. If the target analyte is present in the specimen, it competes with the enzymelabeled drug to bind to a limited amount of specific antibody, that results in more enzyme activity and yield an increased absorbance at 340 nm.
Parameters for HEIA. The HEIA was performed on the Olympus AU400e automated chemical analyzer with a 4-µL sample size, 100 µL of RA, and 100 µL of RE. In the automated chemical analyzer, the sample and RA reagent were mixed and incubated for 5 min before the addition of the RE reagent. The absorbance of the enzyme activity was then measured at 340 nm. Assay performance. To validate the assay performance of the HEIA, sensitivity, precision, drug recovery, stability, and specificity were analyzed. To determine the limit of detection (LOD), carisoprodol drug concentrations at 0, 1, 5, 10, and 15 ng/mL were analyzed in replicates of 20 to establish the mean values and standard deviations, and the calculation of the LOD as the mean plus two standard deviations from the zero calibrator.
The precision of the assay was determined by preparing carisoprodol calibrators and controls by diluting 1 mg/mL drug standard to concentrations of 0, 50, 75, 100, 125, 200, 500, and 1000 ng/mL, and aliquots were analyzed using the Olympus AU400e automated chemical analyzer. The precision (intraday and interday) was determined by analyzing calibrators and controls for four days, with two runs per day. For the drug recovery, carisoprodol-fortified authentic urine samples were tested against the carisoprodol standard calibration curve. Negative authentic urine was spiked at concentrations of 0, 50, 75, 100, 125, 200, 500, and 1000 ng/mL and analyzed on the Olympus 400e automated chemical analyzer.
A stability study was performed on carisoprodol HEIA to determine if the assay performance was stable at 25°C for 21 days. A 200-mL bottle of each carisoprodol G6PDH-conjugate reagent (RE) and carisoprodol antibody reagent (RA) were stored at 25°C unexposed to light for 21 days. The RA and RE were tested at days 1, 3, 7, 14, and 21 to determine if 25°C storage affected the assay performance. A carisoprodol RA and RE stored at 5°C (control) were tested along with the 25°C carisoprodol-G6PDH as a control for the assay performance. To determine specificity, the cross-reactivities of metabolite and commonly used structurally unrelated drugs were analyzed using carisoprodol HEIA.
LC-MS-MS
An Agilent Technologies 1200 series LC pump coupled to a 6410 triple-quadrupole MS, operating in positive electrospray mode (ESI) was used for analysis. The LC column was a Zorbax Eclipse XDB-C 18 Rapid Resolution HT (4.6 × 50 mm, 1.8 micron). The column temperature was held at 40°C, and the injection volume was 5 μL. The mobile phase consisted of 20 mM ammonium formate (pH 6.4, Solvent A) and methanol (Solvent B). At the beginning of the run, the mobile phase composition was 85% A/15% B at a constant flow rate of 0.7 mL/min. After 4 min, the percentage of solvent B was 100%, and at 5 min, the percentage of B returned to 15%. The equilibration time was 3 min. The gas temperature was 350°C, the gas flow was 10 L/min, and the nebulizer pressure was 50 psi. Nitrogen was used as the collision gas, and the capillary voltage was 4000 V.
Two transitions were selected and optimized for carisoprodol and meprobamate. For carisoprodol-d 7 , the precursor ion 268.2 was fragmented to 183.2 at optimized fragment voltage of 60 V and collision energy of 2 V. For carisoprodol, the precursor ion of 261.2 was fragmented to 176.1 (quantitative transition) and 158.1 (qualitative transition) at fragment voltages of 60 V; collision energy of 2 V. For meprobamate, the precursor ion of 219.1 was fragmented to 158.1 (quantitative transition) and 97.1 (qualitative transition) at fragment voltages of 60 V; collision energy of 2 V. Each subsequent analysis required the ratio between the quantitative transition and the qualifying transition to be within ±20% of that established by calibration standards in order to meet the criterion for a positive result.
Validation (LC-MS-MS)
Calibration of the assay, slope, intercept, and correlation coefficients were calculated using linear regression analysis over the calibration range. Peak-area ratios of the target analyte and the internal standard were calculated using Mass Hunter software (Agilent). The data were fit to a linear leastsquares regression curve with a 1/x weighting and not forced through the origin. The linearity of the assay was established with five calibration points, excluding the drug-free matrix. The limit of quantitation, defined as the lowest concentration detectable with a signal-to-noise ratio of at least 10 for the quantifying ion and retention time within 0.2 min of the calibration standard, was determined to be 5 ng/mL for both carisoprodol and meprobamate.
Results and Discussion
Evaluation of enzyme activity
A carisoprodol calibration curve was generated using carisoprodol-fortified urine at calibration points of 0, 50, 100, 200, 500, and 1000 ng/mL. Carisoprodol drug concentration in the specimen was measured in terms of enzyme activity (∆mA/min) in the assay. As shown on the dose-response curve, with an increase in drug concentration in the specimen there was an increase in ∆mA/min or enzyme activity (Figure 2 ).
Sensitivity
The LOD of carisoprodol in urine for the homogeneous enzyme immunoassay was based on the minimum carisoprodol concentration required to produce two standard deviations of absorbance change from the negative calibrator. The LOD for carisoprodol was determined to be 5 ng/mL.
Precision and drug recovery
Intraday and interday precision was determined by analyzing calibrators and controls for 4 days, 2 runs per day, in replicates of 8 [intraday (n = 16), interday (n = 64)]. The percentage CV for intraday rate and interday precision was less than 1% (Table  I) . A percentage drug recovery calculation was made for each known spiked drug concentration. Carisoprodol drug recovery was above 89% (Table II) .
Cross-reactivity with carisoprodol metabolites
An in-house polyclonal antibody that has a higher crossreactivity for carisoprodol and lower cross-reactivity for meprobamate, because meprobamate is administered in higher doses and therefore yields a much longer detection time than carisoprodol in urine, was selected. The cross-reactivity for the meprobamate metabolite is approximately 10%.
Interference with unrelated drugs
Commonly used drugs that are structurally unrelated to carisoprodol were assayed to determine cross-reactivity or interference with the carisoprodol antibody (Table III) . Aliquots of unrelated drugs were spiked into synthetic urine at a concentration of 10,000 ng/mL. None of these compounds produced values in the assay equal to or greater than the assay sensitivity level (5 ng/mL).
Interference with analgesic, related drugs
Commonly used analgesic drugs that may be used in combination with carisoprodol were assayed to determine if these drugs cross-reacted or interfered with the carisoprodol HEIA (Table III) . Aliquots of the drugs were spiked to synthetic urine at a concentration of 10,000 ng/mL. None of these compounds produce values in the assay equal to or greater than the assay sensitivity level (5 ng/mL).
Stability
To determine the preliminary product shelf life of the accelerated stability study, the Q rule technique was applied to project a preliminary shelf life for the product. This rapid technique of determining shelf life is common practice in pharmaceutical and diagnostic industries to estimate product shelf life for an accelerated stability study (13) . In addition, stability studies (accelerated and real time) from previous in-house commercial HEIA kits were taken into account to establish a preliminary product shelf life. For this accelerated stability study, at the 100 ng/mL cutoff of the assay there was no decrease in assay performance when carisoprodol HEIA was stored at 25°C for 21 days, which is equivalent to at least 6 months storage of the HEIA at 5°C. A real-time stability study for this assay is ongoing.
Patient urine samples
Eighty-six urine specimens were donated from various laboratories. These were a mixture of positive and negative for carisoprodol and meprobamate and the confirmation results were provided from the independent facilities. Of the 86 spec- imens, 42 were confirmed negative by LC-MS-MS and 44 specimens were confirmed positive. The specimens were analyzed by carisoprodol HEIA and a comparison between the HEIA and LC-MS-MS was carried out to evaluate the sensitivity, specificity, and accuracy of the HEIA assay. The sensitivity, specificity, and accuracy values are 100%, 100%, and 100%, respectively (Table IV) .
Conclusions
This paper describes the validation of a highly sensitive homogeneous enzyme immunoassay capable of detecting both carisoprodol and meprobamate in urine, using either drug as a calibration standard. The recommended cutoff for carisoprodol is 100 ng/mL and the recommended cutoff for meprobamate is 500 ng/mL. The assay has an LOD of 5 ng/mL and is a reliable method of screening for carisoprodol and meprobamate in urine on a routine basis.
